Krishnaswamy Yeleswaram Sells 500 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) insider Krishnaswamy Yeleswaram sold 500 shares of the business’s stock in a transaction on Friday, April 10th. The shares were sold at an average price of $34.98, for a total transaction of $17,490.00. Following the sale, the insider directly owned 286,016 shares in the company, valued at $10,004,839.68. The trade was a 0.17% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Krishnaswamy Yeleswaram also recently made the following trade(s):

• On Tuesday, April 14th, Krishnaswamy Yeleswaram sold 10,200 shares of Rapport Therapeutics stock. The shares were sold at an average price of $35.08, for a total transaction of $357,816.00.
• On Monday, April 13th, Krishnaswamy Yeleswaram sold 9,165 shares of Rapport Therapeutics stock. The shares were sold at an average price of $34.97, for a total transaction of $320,500.05.
• On Wednesday, April 8th, Krishnaswamy Yeleswaram sold 360 shares of Rapport Therapeutics stock. The shares were sold at an average price of $34.90, for a total transaction of $12,564.00.

Rapport Therapeutics Price Performance

Shares of RAPP stock opened at $36.71 on Thursday. The company’s fifty day simple moving average is $29.79 and its two-hundred day simple moving average is $28.41. Rapport Therapeutics, Inc. has a 1 year low of $7.73 and a 1 year high of $42.27. The stock has a market capitalization of $1.75 billion, a price-to-earnings ratio of -12.84 and a beta of 1.09.

Rapport Therapeutics (NASDAQ:RAPP) last issued its earnings results on Tuesday, March 10th. The company reported ($0.72) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.07). Equities research analysts anticipate that Rapport Therapeutics, Inc. will post -3.65 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on RAPP. Wall Street Zen cut shares of Rapport Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 14th. BTIG Research upped their price target on shares of Rapport Therapeutics to $47.00 and gave the stock a “buy” rating in a report on Monday, March 9th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Rapport Therapeutics in a report on Friday, December 19th. Truist Financial raised shares of Rapport Therapeutics to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, TD Cowen reaffirmed a “buy” rating on shares of Rapport Therapeutics in a report on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $53.83.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in RAPP. Capital International Investors increased its stake in Rapport Therapeutics by 30.7% in the third quarter. Capital International Investors now owns 3,402,529 shares of the company’s stock valued at $101,055,000 after acquiring an additional 800,000 shares during the last quarter. Baker BROS. Advisors LP increased its stake in Rapport Therapeutics by 181.2% in the third quarter. Baker BROS. Advisors LP now owns 1,547,090 shares of the company’s stock valued at $45,949,000 after acquiring an additional 997,000 shares during the last quarter. Maven Securities LTD bought a new position in Rapport Therapeutics in the third quarter valued at $594,000. Swedbank AB bought a new position in Rapport Therapeutics in the fourth quarter valued at $3,434,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Rapport Therapeutics by 64.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock valued at $70,000 after acquiring an additional 905 shares during the last quarter.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.